In hematological malignancies, loss of function mutations of EZH2 are reported in T-cell acute lymphocytic leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, however, gain of function mutations are observed in B-cell lymphomas [10]. This evidence concerns the gene EZH2 and cancer.